



09/20/02

DT19 Rec'd CT/PTO

27 SEP 2002

m-s
H/T
S/C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/807,647

Filed: 6/29/2001

1st Inventor: OI, SatoruFor: 1,5-Benzodiazepine Compounds, Their Production and
Use

Atty. Dkt. No. 2560 USOP

Art Unit: tba

Examiner: tba

Allowed:

Batch:

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 082656127 US

DATE IN: September 27, 2002

Itemized Papers/Items:


1. This Postcard and Certificate of Express Mailing (2 pages)
2. Transmittal Form (1 page X 2)
3. Response to Notice of Defective Response (1 page), Submission of CRF of Sequence Listing (3pages), IBM PC/AT format disk containing the CRF of the Sequence Listing, and copy of Notification of Missing Requirements (6 pages).

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

Commissioner for Patents
Washington, D.C. 20231.

on this date, 9/27/02

Dated: 9/27/02


Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA


Please type a plus sign (+) inside this box →

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

Please type a plus sign (+) inside this box → **[+]**

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

 TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/807,647	
	Filing Date	6/29/2001	
	First Named Inventor	Satoru OI	
	Group Art Unit	tba	
	Examiner Name	tba	
Total Number of Pages in This Submission	14	Attorney Docket Number	2560 USOP


ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request		<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard. Certificate of Express Mailing; Submission of CRF of Sequence Listing IBM PC/AT Format Disk Copy of Notice of Missing Parts
<input type="checkbox"/> Express Abandonment Request		
<input type="checkbox"/> Information Disclosure Statement		
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input checked="" type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks


The Commissioner is hereby authorized to
charge any additional fees which may be
required, or credit any overpayment to
Deposit Account 500799.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Mark Chao, Ph.D., JD, Reg. No. 37,293
Signature	
Date	9/27/02

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class
mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: **9/27/02**

Typed or printed name	Gail L. Winokur
Signature	
Date	9/27/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Express Mail EV 082656127 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	09/807,647	Art Unit:	tba
Filed:	6/29/2001	Examiner:	tba
1 st Inventor:	OI, Satoru	Allowed:	
For:	1,5-Benzodiazepine Compounds, Their Production and Use	Batch:	
Atty. Dkt. No.	2560 US0P	Paper No.:	

Sequence Listing Requirements

O I P E
 SEP 27 2002
 JCHS
 PATENT & TRADEMARK OFFICE
 Commissioner for Patents
 Washington, D.C. 20231
 Sir:

In response to the Notice of Defective Response mailed 09/09/2002, Applicants respectfully submit, a substitute written Sequence Listing and a DOS Text CRF Sequence Listing file "2560us0p.seq.txt" on the enclosed 3.5" IBM PC/AT computer disk.

The undersigned hereby certifies that the CRF and the written Sequence Listing are the same in content.

Respectfully submitted,

Dated: September 23, 2002

(847)383-3372
 (847)383-3391

Mark Chao, Ph.D., Reg. No. 37,293
 Elaine M. Ramesh, Ph.D., Reg. No. 43032
 Attorney for Applicants
 Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
 Intellectual Property Department
 Suite 500, 475 Half Day Road
 Lincolnshire, IL 60069 USA

COPYUNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box P.O. 1
 United States Patent and Trademark Office
 Washington, D.C. 20231
www.uspto.gov


U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/807,647	Satoru OI	2560USOP
INTERNATIONAL APPLICATION NO.		
PCT/JP99/05754		
I.A. FILING DATE	PRIORITY DATE	
10/19/1999	10/20/1998	
CONFIRMATION NO. 2246		
371 FORMALITIES LETTER		
 *OC00000008747807*		

Date Mailed: 09/09/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration



The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable

BEST AVAILABLE COPY

form must be submitted as required by 37 CFR 1.825(d).

■ **APPLICANT MUST PROVIDE:**

- An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

KAYA L LEWIS BALTIMORE

Telephone: (703) 305-3695

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/807,647	PCT/JP99/05754	2560USOP

FORM PCT/DO/EO/916 (371 Formalities Notice)

BEST AVAILABLE COPY